Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

dc.contributor.authorGalvez, Nicolas M. S.
dc.contributor.authorPacheco, Gaspar A.
dc.contributor.authorSchultz, Barbara M.
dc.contributor.authorMelo-Gonzalez, Felipe
dc.contributor.authorSoto, Jorge A.
dc.contributor.authorDuarte, Luisa F.
dc.contributor.authorGonzalez, Liliana A.
dc.contributor.authorRivera-Perez, Daniela
dc.contributor.authorRios, Mariana
dc.contributor.authorBerrios, Roslye, V
dc.contributor.authorVazquez, Yaneisi
dc.contributor.authorMoreno-Tapia, Daniela
dc.contributor.authorVallejos, Omar P.
dc.contributor.authorAndrade, Catalina A.
dc.contributor.authorHoppe-Elsholz, Guillermo
dc.contributor.authorIturriaga, Carolina
dc.contributor.authorUrzua, Marcela
dc.contributor.authorNavarrete, Maria S.
dc.contributor.authorRojas, Alvaro
dc.contributor.authorFasce, Rodrigo
dc.contributor.authorFernandez, Jorge
dc.contributor.authorMora, Judith
dc.contributor.authorRamirez, Eugenio
dc.contributor.authorGaete-Argel, Aracelly
dc.contributor.authorAcevedo, Monica L.
dc.contributor.authorValiente-Echeverria, Fernando
dc.contributor.authorSoto-Rifo, Ricardo
dc.contributor.authorWeiskopf, Daniela
dc.contributor.authorGrifoni, Alba
dc.contributor.authorSette, Alessandro
dc.contributor.authorZeng, Gang
dc.contributor.authorMeng, Weining
dc.contributor.authorGonzalez-Aramundiz, Jose, V
dc.contributor.authorJohnson, Marina
dc.contributor.authorGoldblatt, David
dc.contributor.authorGonzalez, Pablo A.
dc.contributor.authorAbarca, Katia
dc.contributor.authorBueno, Susan M.
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2025-01-20T21:01:37Z
dc.date.available2025-01-20T21:01:37Z
dc.date.issued2022
dc.description.abstractBackground: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in China, Brazil, Indonesia, Turkey, and Chile. Methods: This study is a randomized, multicenter, and controlled phase 3 trial in healthy Chilean adults aged & GE;18 years. Volunteers received two doses of CoronaVac separated by 2 (0-14 schedule) or 4 weeks (0-28 schedule); 2302 volunteers were enrolled, 440 were part of the immunogenicity arm, and blood samples were obtained at different times. Samples from a single center are reported. Humoral immune responses were evaluated by measuring the neutralizing capacities of circulating antibodies. Cellular immune responses were assessed by ELISPOT and flow cytometry. Correlation matrixes were performed to evaluate correlations in the data measured. Results: Both schedules exhibited robust neutralizing capacities with the response induced by the 0-28 schedule being better. No differences were found in the concentration of antibodies against the virus and different variants of concern (VOCs) between schedules. Stimulation of peripheral blood mononuclear cells (PBMCs) with Mega pools of Peptides (MPs) induced the secretion of interferon (IFN)-gamma and the expression of activation induced markers in CD4(+) T cells for both schedules. Correlation matrixes showed strong correlations between neutralizing antibodies and IFN-gamma secretion. Conclusions: Immunization with CoronaVac in Chilean adults promotes robust cellular and humoral immune responses. The 0-28 schedule induced a stronger humoral immune response than the 0-14 schedule.
dc.fuente.origenWOS
dc.identifier.doi10.7554/eLife.81477
dc.identifier.issn2050-084X
dc.identifier.urihttps://doi.org/10.7554/eLife.81477
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92924
dc.identifier.wosidWOS:000876741000001
dc.language.isoen
dc.revistaElife
dc.rightsacceso restringido
dc.subjectCoronaVac
dc.subjectphase 3 clinical trial
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectvaccines
dc.subjectimmunization
dc.subjectHuman
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleDifferences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
dc.typeartículo
dc.volumen11
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files